Actionable MAPK pathway alterations by tumor type. A total of 115 alterations were detected in 112 tumors. (A) Tumor diagnoses with actionable MAPK pathway alterations identified. (B-G) Specific MAPK alterations detected in selected diagnostic groups and tumor types. The number of alterations in each group is shown. (B) All tumors, (C) non-CNS solid tumors, (D) CNS solid tumors, (E) RMS, (F) LGG, and (G) HGG. HGG, high-grade glioma; LGG, low-glade glioma; MAPK, mitogen-activated protein kinase; MPNST, malignant peripheral nerve sheath tumor; RMS, rhabdomyosarcoma.